Welcome to the board. I've got orders in for "bottom shopping" today at 4.64 and 4.50. Today should be the last day of selling pressure moving into the new year. ESTABLISH-2 is very much de-risked and the trial has been designed with FDA input. CEO, Jeff Stein, expects better results due to the higher bioavailability of the IV formulation. If history repeats itself, we may see a similar run-up that we saw going into ESTABLISH-1. My price target is around $7 on the run-up. Trius has tapped the ATM twice... the first time for around 3 million and the second around 5 million. That would leave about 17 million left.